A

    Azitra Inc (AZTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.17
    -0.00 (-1.24%)

    Market Cap: $10.72M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(6/9)
    Avg Surprise
    -57.50%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.35-775.0%
    60d ago$-0.27-575.0%
    30d ago$-0.02+50.0%
    7d ago$-0.04+0.0%
    Current$-0.04
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$0.01
    Range$0.01 - $0.03
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.04---
    Jun 26
    		$-0.17$-0.21+19.05%Beat+85.8%
    Mar 26
    		$-0.25$-0.04-525.00%Miss-8.7%
    Dec 25
    		$-1.17$-0.32-265.63%Miss+44.0%
    Sep 25
    		$-0.67$-0.77+12.99%Beat+79.7%
    Jun 25
    		$-1.20$-1.40+14.29%Beat+93.4%
    Mar 25
    		$-0.23$0.00N/ABeat+94.7%
    Dec 24
    		$-2.09$-3.33+37.24%Beat-107.5%
    Sep 24
    		$-3.30$-3.20-3.13%Miss-1962.5%
    Jun 24
    		$-18.25$-21.45+14.92%Beat+78.2%
    Mar 24
    		$-4.36$0.00N/ABeat-
    Dec 23
    		$27.97$-35.96+177.78%Beat-
    Sep 23
    		$-0.16N/AN/ABeat-
    Jun 23
    		$-83.78N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.08EV/EBITDA-0.39x
    Price/FCF-0.30xFCF Yield-331.37%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-256.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-1165.91x
    Current Ratio4.86xQuick Ratio4.86x
    Trading Statistics
    Beta-1.18Avg Volume3.28M
    52-Week High$1.0452-Week Low$0.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.15
    SMA 20$0.15
    SMA 50$0.15
    SMA 200$0.22
    EMA 10$0.16
    EMA 20$0.15
    EMA 50$0.16
    EMA 200$0.35

    MACD

    Line: 0.01Signal: 0.00Hist: 0.01

    ADX

    ADX: 25.3+DI: 30.3-DI: 9.6

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down68.0
    PSAR$0.14

    Bollinger Bands

    Upper Band$0.18
    Lower Band$0.11
    %B Position5039%(Upper)
    Band Width0.90

    RSI (14-Day)

    Neutral
    64.4

    Momentum Oscillators

    Stoch %K85.1
    Stoch %D86.1
    Williams %R-21.7
    ROC (10d)29.1%
    Momentum0.04
    CCI (20d)140.5
    MFI (14d)89.9

    Volatility Measures

    ATR (14d)$0.01(8.3%)
    StdDev (20d)0.02
    Hist Vol82.2%(High)

    Volume Flow

    VWAP$0.17
    OBV1.2B
    AD Line17.6B
    CMF (20d)0.256

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.15

    Pivot Points

    R3$0.21
    R2$0.20
    R1$0.19
    Pivot Point$0.18
    S1$0.17
    S2$0.16
    S3$0.15

    Advanced Oscillators

    TSI18.07
    Ultimate Osc59.4
    KST97.18

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$7.49M$0$7,500$0$90,000$310,700
    Cost of Revenue$0$0$113,104$0$0$0$115,748$0$0$0N/A$0
    Gross Profit$0$0$-113,104$0$0$0$-115,748$0$7,500$0$90,000$310,700
    Operating Expenses$3.42M$3.93M$2.23M$2.77M$2.87M$3.10M$2.43M$2.93M$2.67M$2.96M$2.56M$2.30M
    R&D$1.35M$1.56M$1.00M$1.18M$1.40M$1.25M$1.12M$1.02M$1.12M$1.47M$1.51M$548,524
    SG&A$2.07M$2.37M$1.22M$1.59M$1.47M$1.85M$1.32M$1.91M$1.55M$1.49M$1.05M$1.76M
    Operating Income$-3,419,168$-3,933,924$-2,226,591$-2,768,484$-2,871,352$-3,100,238$-2,434,156$-2,929,207$-2,660,280$-2,961,497$-2,470,477$-1,993,732
    Interest Income$74,661$14,719$12,761$4,823$15,461$37,164$51,287$47,389$16,268$7,609$394$634
    Interest Expense$1,365$3,411$5,454$372$468$1,293$5,612$3,851$1,782$915$997$710
    Income Before Tax$-3,347,660$-3,927,240$-2,225,185$-2,764,528$-2,888,993$-3,068,345$-2,384,102$-1,009,491$-2,631,993$-2,932,875$-2,446,191$-1,943,289
    Income Tax Expense$0$0$8,319$0$0$0$9,031$0$0$0$7,593$0
    Net Income$-3,347,660$-3,927,240$-2,233,504$-2,764,528$-2,888,993$-3,068,345$-2,393,133$-1,009,491$-2,631,993$-2,932,875$-2,453,784$-1,943,289
    EBITDA$-3,307,394$-3,821,895$-2,119,388$-2,656,978$-2,793,416$-2,986,944$-2,314,029$-949,396$-2,532,538$-2,824,656$-2,282,479$-1,830,709
    EBIT$-3,420,956$-3,938,548$-2,232,492$-2,768,979$-2,904,040$-3,104,359$-2,429,777$-1,053,029$-2,646,479$-2,939,569$-2,390,980$-1,943,213
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AZTR

    News

    $Azitra (AZTR.US)$ Not letting me sell my shares when it's finally moving again after a month of fucking holding and waiting. Cheating MOTHER F...ERS

    An investor is expressing extreme frustration with Moomoo, claiming they are unable to sell their shares of Azitra (AZTR.US) despite the stock finally showing upward movement after a month of holding. The user suspects foul play, referring to the situation as "cheating." The post is a complaint within the Moomoo community forum.

    Moomoo•8/24/26•
    Bearish

    Azitra (NYSE: AZTR) wins back listing under new NYSE watch period

    Azitra, Inc. (AZTR) has regained compliance with NYSE American's continued listing standards, leading to the removal of its "below compliance" indicator. While the company is now compliant, it will remain under NYSE American's monitoring for 12 months, during which any new noncompliance could result in expedited delisting proceedings. Azitra is advancing its clinical programs, ATR-COSF and ATR-04, the latter of which has FDA Fast Track designation for EGFR inhibitor-associated rash.

    Stock Titan•8/22/26•
    Somewhat-Bullish

    Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

    Azitra, Inc. announced it has regained compliance with NYSE American's continued listing standards. The company resolved previously disclosed deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Azitra will continue to focus on advancing its ATR-COSF and ATR-04 programs, maintaining financial discipline and governance.

    PR Newswire•8/22/26•
    Bullish

    Azitra regains compliance with NYSE American listing standards, removing noncompliance status.

    Azitra, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with all NYSE American continued listing standards. This resolution removes the 'below compliance' indicator, though the company remains under monitoring. Azitra is now focusing on advancing its dermatology and cosmetic protein programs, aiming to build shareholder value through its innovative therapies.

    Pluang•8/22/26•
    Bullish

    Azitra regains compliance with NYSE American listing standards

    Azitra Inc. has announced it has regained full compliance with NYSE American's continued listing standards, resolving previously disclosed deficiencies. The biopharmaceutical company received written notification from NYSE American LLC confirming its adherence to all listing requirements. Azitra will continue to be monitored by NYSE Regulation, with potential for accelerated delisting proceedings if new deficiencies arise within 12 months.

    Investing.com•8/22/26•
    Bullish

    Frequently Asked Questions About AZTR

    Does AZTR pay dividends?
    Azitra Inc (AZTR) does not currently pay a regular dividend.
    What is AZTR's market cap?
    Azitra Inc (AZTR) has a market capitalization of $10.72M with a current stock price of $0.17.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In